The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
amgen stock drops as analysts debate weight loss drug safety concerns
Amgen's stock dropped over 7% as analysts evaluated bone density loss data from an early trial of its weight loss drug, MariTide. While some analysts raised concerns about potential safety risks linked to higher doses, others deemed the market reaction an overreaction, emphasizing the need for more extensive data from upcoming phase two trials.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.